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Introduction
Resistance of chemo-therapeutic drugs such as adriamycin and paclitaxel is one of the well-known failures of cancer therapy. Over 90% of patients with metastatic cancer are known to fail cancer therapy because of drug resistance [1] . To evade toxic effect, drug resistant cancer cells usually increase the rates of drug efflux, alterations in drug metabolism and mutation of drug targets in their intracellular regions [2] . MDR1, also known as P-glycoprotein, is a 170kDa protein that belongs to the sub-family of the ATPbinding cassette (ABC) transporters as one of drug resistance molecules [3] . The function of MDR1 has been described as an ATP-dependent efflux pump of chemo-therapeutic drugs. Actually, overexpression of MDR1 is one of the common phenotype of drug resistant cancers in which intracellular accumulation of chemo-therapeutic drugs is significantly decreased [4, 5] . For this reason, recent studies has focused on the suppression of MDR1 expression or function to overcome the MDR1-mediated drug resistance [6] . In general, three options to control ABCB1 gene encoding MDR1 protein are regulation of several oncogenes including Ras, c-Raf, and related protein kinases, epigenetical change of ABCB1 promoters, and transcriptional factors such as C/EBP-β in malignant cancer cells [7] .
Recently some natural compounds are on the spotlight due to their safe and efficient antitumor activities in several resistant cancers by single or combination treatment with classical anti-cancer agents. Tannic acid showed synergistic antitumor effect by modulating efflux pump system with chemo-therapeutic drugs [8] . Eigallocatechin gallate (EGCG), the most abundant polyphenol compound in green tea, mediated cell growth arrest and inhibited MDR1 expression in adriamycin-resistant cancer cells [9] . Though our group reported that CB-PIC induces AMP-activated protein kinase (AMPK) mediated apoptosis in hypoxic colon cancer cells [10] , the underlying antitumor mechanism of CB-PIC was not yet examined in resistant cancer cells. Thus, in the current study, the potential role of CB-PIC targeting MDR1 was elucidated in paclitaxel resistant lung cancer (H460/PT), adriamycin or adriamycin resistant breast cancer (MCF7/Adr) and colon cancer (HCT15/cos) cells.
Materials and Methods
Chemicals and reagents CB-PIC ( Fig. 1 
Cytotoxicity assay
To determine the sensitizing effect of CB-PIC with chemo-therapeutic drugs in drug resistant cells, 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay was performed. Briefly, the cells (1×10 4 cells / well) were seeded onto 96-well culture plates. After incubation for 24 h, cells were exposed to various concentrations of CB-PIC, adriamycin, paclitaxel alone or combination for 48 h. Then, 100 μl of 1 mg/ml MTT (Sigma Aldrich, USA) was added to each well for 4 h at 37℃. The purple formazan formed was solubilized by DMSO and absorbance at 590 nm was read by a microplate reader (Molecular Devices Co, Sunnyvale, CA, USA). Cell viability was calculated as a percentage of viable cells versus untreated cells by following equation
Western blot Cells were lysed in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 2 mM EDTA, and 1% TritonX-100) containing protease inhibitors (Roche, Germany), and phosphatase inhibitors (Sigma Aldrich, USA). Protein samples were quantified by Bio-Rad DC protein assay kit (Bio-Rad, Hercules, CA, USA) The protein samples were separated on 8 to 12% SDS-polyacrylamide gels, and transferred to nitrocellulose membranes. Membranes were incubated with primary antibodies of MDR1, p-AKT, AKT, p-STAT3, STAT3, Bcl-2, survivin, Bcl-XL, p53, β-actin (Cell Signalling, Beverly, MA) diluted in 5% BSA in TBS-Tween 20 (1:1000-1:5000) for overnight at 4℃, washed with TBS-Tween 20, and incubated with HRP-conjugated secondary antibodies (1:5000-1:20000) for 30 min at RT. Expression was visualized by using ECL Western blotdetection reagent (GE Healthcare, UK).
RT-PCR
Total RNA was isolated with QIAzol (Invitrogen, USA) and cDNA was reverse-transcribed with MML-V reverse transcriptase kit (Enzynomics, Daejeon, Korea). Primer sequences used for PCR are as follows: MDR1 forward 5'-AGGCCAACATACATGCCTTC-3', MDR1 reverse 5'-GCTCCTTGACTCTGCCATTC-3'; glyceraldehyde-3-phosphate dehydrogenase (GAPDH) forward 5'-TATAAATTGAGCCCGCAGCC-3', GAPDH reverse 5'-TTCCCGTTCTCAGCCTTGAC-3'. The PCR was performed as follows: 5 min at 95℃, 30 cycles of 95℃ for 30 s, 56℃ for 30 s, 72℃ for 45 s, and 5 min incubation at 72℃. The PCR products were loaded onto 1% agarose gel electrophoresis and visualized by loading STAR solution (Dyne-bio, Sungnam, Korea) and UV illumination.
Rhodamine 123 efflux assays -Short term direct effect on MDR1 enzyme activity; H460/PT cells (1×10 5 cells / well) were exposed to 2 μM of Rhodamine 123 in growth medium for 30 min to allow uptake of Rhodamine123. Then the cells were washed twice with PBS, resuspended in fresh medium with or without 10 μM of CB-PIC or EGCG and incubated for 60 min. Cells were immediately moved on ice to stop reaction. Rhodamine 123 uptake at baseline and efflux was immediately measured by flow cytometry.
-Long term accumulation assay; H460/PT or H460 cells (1×10 5 cells / well) were pre-treated with or without 20 μM of CB-PIC for 24 h and incubated with 5 μM of Rhodamine 123 for another 6 h at 37℃. Cells were then pelleted, washed twice, and resuspended in FACS buffer. Rhodamine 123 uptake at baseline and efflux was immediately measured by flow cytometry.
Cell cycle detection
Cell cycle detection was performed by Propidium iodide (PI) staining. Cells were fixed in 70% Ethanol for 1 h at 4℃ and incubated in PBS with 0.1% RNase A for 1 h at 37℃ and suspended in PBS containing 50 µg / ml PI for 1 h at room temperature. Stained cells were analyzed by using FACSCalibur (Becton Dickinson, Franklin Lakes, NJ, USA)
Combination index
To determine the synergistic effect of CB-PIC and chemo-therapeutic drugs, MTT assay was performed in three resistant cell lines. Following the determination of IC 50 for each drug, the synergy between CB-PIC and adriamycin or paclitaxel was evaluated through combination index values by the method of Chou Talalay [11] using CalcuSyn software (Biosoft, USA).
Statistical analysis
Data were presented as mean ± standard deviation (SD). The statistically significant differences between sample and untreated control cells were calculated by Student's t-test. All experiments were carried out at least thrice. 
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Results
MDR1 was overexpressed in drug resistant (DR) cancer cells compared to their parental cells
In the drug sensitivity assay of the drug resistance cell lines such as HCT15/cos, MCF7/ Adr and H460/PT, most drug resistant cells were survived even in high concentration of Adr or PT, while IC50 of parental cells was less than 1 μM (HCT15 and MCF7) of Adr or 0.5 μM of PT (H460) (Fig. 1A and B) . To confirm whether MDR1 is overexpressed in DR cells, HCT15/cos, MCF7/Adr and H460/PT cells, immunoblotting and FACS analysis were carried out. Western blotting showed overexpression of MDR1 protein (Fig. 1C) and flow cytometry analysis revealed cell surface expression of MDR1 in resistant cells compared to parental cells (Fig. 1D) . Next, we measured Rhodamine 123 accumulation by flow cytometry to determine the efflux capacity of DR cells. As shown in Fig. 1E , Rhodamine 123 was highly accumulated in parental cancer cells compared to DR cancer cells, indicating that DR cells actively pump MDR1 substrate Rhodamine 123 out of cells compared to parental cells (Fig.  1E ). These data demonstrate that all of tested DR cancer cells exhibit the upregulation of MDR1 protein and resistance to chemotherapeutic agents.
CB-PIC exerted cytotoxicity in DR cells
To verify whether CB-PIC affects the viability of DR cells, we conducted MTT assay in CB-PIC treated DR cancer cells. We found that CB-PIC dramatically decreased the viability of DR cells (Fig. 2B and C) . Especially, cell death in H460/PT was significantly occurred more than parental cells by CB-PIC treatment (Fig. 2C) . Next, we confirmed the effect of CB-PIC on 
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Fa points were not below 1. These data suggest that combination treatment of CB-PIC with chemo-drug synergistically show the effect on various DR cells to overcome resistance.
Discussion
Though many chemo-therapeutic agents contributed to several cancers for years, acquired resistance is a hot issue especially in relapsed cancers [13] [14] [15] . MDR1, also known as p-glycoprotein and encoded by ABCB1 gene, is a subunit of ATP-dependent transporter and a molecular target for multidrug resistance [16] . MDR1 transports substrates like microtubule poisons with ATP hydrolysis across membrane [2, 17] . Though MDR1 inhibitors including verapamil have been used with chemo-therapeutic drugs [18] , development of new MDR1 inhibitors with little toxicity and better efficacy are required [19] .
Accumulated evidences show that natural compounds such as quercetin, (-)-epigallocatechin gallate (EGCG), curcumin, capsaicin, and 6-gingerol are effective in drug resistance in a variety of cancers [20] [21] [22] [23] . Among them EGCG and curcumin regulated MDR1 via direct inhibition of active region of p-glycoproteins and its substrates [21, 22] . Amphiphilic chemical structure of EGCG facilitated the interaction with P-glycoprotein [21] and curcumin suppressed P-glycoprotein in KB-C2 (KB-C2/PG) cancer cells ectopically Cellular Physiology and Biochemistry expressing MDR1 [22] . However, in the current study, though CB-PIC did not directly inhibit MDR1 activity (Fig. 4A) , it attenuated the expression of MDR1 at protein and mRNA levels in all tested DR cells in a time and dose dependent manner. Furthermore, CB-PIC suppressed the viability of resistant cancer cells, such as MCF7/Adr, H460/PT and HCT15/cos compared to parental cells, indicating the potent sensitizing effect of CB-PIC in DR cells. Consistently, CB-PIC effectively induced the active form of PARP and caspase 9, increased sub G1, in PT and Adr resistant cancer cells, implying the cytotoxic effect of CB-PIC is exerted via apoptosis induction and MDR1 inhibition. It is well documented that many transcription factors, such as Ap-1, NF-kB, Akt and STAT3 are involved in activation of MDR1 gene in various cancers [24] [25] [26] [27] [28] [29] . STAT3 binds to the potential promoter region, +64 and +72 of MDR1 in myeloid leukemia. Based on our results, we validated that transcriptional repression of MDR1 gene is mediated by suppression of phosphorylation of Akt and STAT3. In addition, CB-PIC sensitized resistant cancer cells to Adr via downregulation of survival proteins such as survivin, Bcl-xL and Bcl-2 in HCT15/ cos cells, indicating inhibition of survival genes mediates apoptosis induction of CB-PIC in resistant colorectal cancer cells. However, further studies to show how CB-PIC regulates Akt and STAT3 are required.
Taken together, our findings suggest that CB-PIC suppresses MDR1 expression via inhibition of STAT3 and AKT signalling to overcome drug resistance in chemo-resistant cancer cells as a potent chemotherapeutic sensitizer.
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